Literature DB >> 18438105

A comparison of anionic nanoparticles and microparticles as vaccine delivery systems.

Janet Wendorf1, James Chesko, Jina Kazzaz, Mildred Ugozzoli, Michael Vajdy, Derek O'Hagan, Manmohan Singh.   

Abstract

The objective of this work was to conduct an in vivo comparison of nanoparticles and microparticles as vaccine delivery systems. Poly (lactide-co-glycolide) (PLG) polymers were used to create nanoparticles size 110 nm and microparticles of size 800-900 nm. Protein antigens were then adsorbed to these particles. The efficacy of these delivery systems was tested with two protein antigens. A recombinant antigen from Neisseria meningitides type B (MenB) was administered intramuscularly (i.m.) or intraperitonealy (i.p.). An antigen from HIV-1, env glycoprotein gp140 was administered intranasally (i.n.) followed by an i.m. boost. From three studies, there were no differences between the nanoparticles and micro-particles formulations. Both particles led to comparable immune responses in mice. The immune responses for MenB (serum bactericidal activity and antibody titers) were equivalent to the control of aluminum hydroxide. For the gp140, the LTK63 was necessary for high titers. Both nanoparticles and microparticles are promising delivery systems.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18438105     DOI: 10.4161/hv.4.1.4886

Source DB:  PubMed          Journal:  Hum Vaccin        ISSN: 1554-8600


  16 in total

Review 1.  Physical and chemical strategies for therapeutic delivery by using polymeric nanoparticles.

Authors:  José M Morachis; Enas A Mahmoud; Adah Almutairi
Journal:  Pharmacol Rev       Date:  2012-04-27       Impact factor: 25.468

Review 2.  Peptide/protein vaccine delivery system based on PLGA particles.

Authors:  Mojgan Allahyari; Elham Mohit
Journal:  Hum Vaccin Immunother       Date:  2016-03-03       Impact factor: 3.452

3.  Relationship between the size of nanoparticles and their adjuvant activity: data from a study with an improved experimental design.

Authors:  Xinran Li; Brian R Sloat; Nijaporn Yanasarn; Zhengrong Cui
Journal:  Eur J Pharm Biopharm       Date:  2010-12-21       Impact factor: 5.571

4.  Nanoparticle delivery of donor antigens for transplant tolerance in allogeneic islet transplantation.

Authors:  Jane Bryant; Kelan A Hlavaty; Xiaomin Zhang; Woon-Teck Yap; Lei Zhang; Lonnie D Shea; Xunrong Luo
Journal:  Biomaterials       Date:  2014-07-25       Impact factor: 12.479

Review 5.  Nano-microparticles as immune adjuvants: correlating particle sizes and the resultant immune responses.

Authors:  Moses O Oyewumi; Amit Kumar; Zhengrong Cui
Journal:  Expert Rev Vaccines       Date:  2010-09       Impact factor: 5.217

Review 6.  Current advances in research and clinical applications of PLGA-based nanotechnology.

Authors:  Jian-Ming Lü; Xinwen Wang; Christian Marin-Muller; Hao Wang; Peter H Lin; Qizhi Yao; Changyi Chen
Journal:  Expert Rev Mol Diagn       Date:  2009-05       Impact factor: 5.225

7.  Aluminum hydroxide nanoparticles show a stronger vaccine adjuvant activity than traditional aluminum hydroxide microparticles.

Authors:  Xinran Li; Abdulaziz M Aldayel; Zhengrong Cui
Journal:  J Control Release       Date:  2013-11-01       Impact factor: 9.776

8.  Strong antibody responses induced by protein antigens conjugated onto the surface of lecithin-based nanoparticles.

Authors:  Brian R Sloat; Michael A Sandoval; Andrew M Hau; Yongqun He; Zhengrong Cui
Journal:  J Control Release       Date:  2009-09-01       Impact factor: 9.776

Review 9.  Applying biodegradable particles to enhance cancer vaccine efficacy.

Authors:  Kawther K Ahmed; Sean M Geary; Aliasger K Salem
Journal:  Immunol Res       Date:  2014-08       Impact factor: 4.505

Review 10.  Mitochondrion: A Promising Target for Nanoparticle-Based Vaccine Delivery Systems.

Authors:  Ru Wen; Afoma C Umeano; Lily Francis; Nivita Sharma; Smanla Tundup; Shanta Dhar
Journal:  Vaccines (Basel)       Date:  2016-06-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.